| Revenue growth | Q2 revenue +21% YoY to ₹2,370 Cr; H1 +19% to ₹4,599 Cr. |
|---|---|
| Margins | EBITDA margins fell YoY; H2 guided mid-teens, improving QoQ. |
| Order book | Line 4 book strongest ever; 23 active proposals; no order book figure disclosed. |
| Demand visibility | US isolator demand strong; Line 4 RFPs at record; 23 active proposals. |
| Management confidence | Balanced; confident H2 recovery, but FY28 guidance deferred. |
Growth
Q2 revenue +21% YoY, H1 +19%; broad-based, but EBITDA margins fell YoY on Montreal and SPECT shortfall.
Outlook
H2 average EBITDA margin mid-teens; FY27 capex ₹1,800–1,900 Cr, FY28 ~₹1,000 Cr; net debt ~₹4,000 Cr end-FY27.
Risks
Montreal losses (₹157 Cr H1 plus ~₹200 Cr earlier) and SPECT supply gaps; FY28 guidance deferred; API pricing pressure.
Last quarter's promises, checked
Delivered
- Guided FY27 growth 'low double digits' → H1 +19% (= BEAT)
Partly delivered
- Guided Line 3 FY27 revenue $60–80M → ~$20M in Q2 (= PARTIAL)
- Guided Ruby-Fill '30%+' growth → ~30% annualised Q2 (= PARTIAL)
Missed
- Guided H2 EBITDA margin 17–18% → now 'mid-teens' (= MISS)
- Guided Montreal FY27 loss ~FY26's ~₹200 Cr → H1 alone ₹157 Cr (= MISS)
- Guided capex ~₹1,668 Cr and net debt falling from FY28 → capex ₹1,800–1,900 Cr, net debt ~₹4,000 Cr end-FY27 (= MISS)
Earnings Call Transcript filed with BSE, NSE: JUBLPHARMA. Summary written with AI assistance from the document.
Jubilant Pharmova Ltd: key numbers
- Share price
- ₹935.05
- Market cap
- ₹14,894 Cr
- Revenue (annual)
- ₹8,280 Cr
- Net profit (annual)
- ₹398.5 Cr
- P/E (TTM)
- 56.6×Sector 49.0×
- Promoter holding
- 47.68%+0.00% QoQ
- FII holding
- 15.37%Current quarter
Reference market data from a third-party provider, updated daily. Not a valuation or a recommendation.
More from Jubilant Pharmova Ltd
All →Jubilant Pharmova Debt & Borrowing
Jubilant Pharmova's postal ballot approved a special resolution for issuing Non-Convertible Debentures on a private placement basis, with 99.39% votes in favour. The NCD issue approval is a debt-raising step, so it is classified as Debt & Credit.
Jubilant Pharmova Annual General Meeting
Jubilant Pharmova shareholders passed a special resolution approving private placement of Non-Convertible Debentures via postal ballot. Voting results show 99.39% in favour of the NCD issuance.
Jubilant Pharmova Employee Stock Options
Jubilant Pharmova approved a grant of 1,907 RSUs to eligible employees under its 2018 ESOP plan. No monetary event value is disclosed.
- Execution
- Vesting over 3 years from the date of grant; exercisable within 1 year of vesting
Jubilant Pharmova Results Update
Q2 revenue rose 21% to Rs 2,370 Cr, but EBITDA fell 27% and PAT dropped to Rs 31 Cr. SPECT supply gaps and remediation costs compressed margins.
Jubilant Pharmova Q2 FY27 Results: Net Profit ₹31 Cr, Down 74.1% YoY
Jubilant Pharmova Ltd reported revenue from operations of ₹2,370 Cr (+20.5% YoY) and net profit of ₹31 Cr (-74.1% YoY) for Q2 FY27.
- Key figure
- Net profit ₹31 Cr · -74.1% YoY
Jubilant Pharmova Business Update
Jubilant Pharmova's subsidiary Jubilant Therapeutics will present preliminary Phase 1 clinical data for JBI-802 at the 68th ASH meeting. A company event on December 14, 2026 will discuss the data.